Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis

Overview of attention for article published in NEJM Evidence, August 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 6 news outlets
policy: 1 policy source

twitter: 31 X users
facebook: 1 Facebook page

Readers on

mendeley: 49 Mendeley

So far, Altmetric has seen 36 X posts from 31 X users, with an upper bound of 105,200 followers.

@aditya_gan3500 This was a review of the historical dose -https://t.co/VckTCznVzG This is a high-dose trial on rifampicin, there are 2-3 ongoing trials also https://t.co/qcUNiAcA9x Also common question on rounds....

Today is #WorldTBDay. #TB remains the leading cause of death among all the communicable diseases. However, WHO has now rolled out a four-month treatment which offers some hope in the increase in cure rates, reduced mortality, reduced transmission of TB.…

RT @Tb_JournalClub: Thanks so much to @ChrisDCousins & @SeanWasserman for signing off 2023 with an outstanding round-up of the #RIFASHORT #…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 32 additional X posts.